Arovella Therapeutics Ltd has released a press release.
SUDA Placement Raises $3.65m
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Investor Presentation incorporating iNKT Cell Platform
- SUDA Licenses a Novel iNKT Cell Therapy Platform
- Investor Presentation March 2021
- Anagrelide Project Update
- Appendix 4D & Interim Financial Half Year Report FY2021
Later from Arovella Therapeutics
- Disclosure Document Prospectus $3.65m
- SUDA appoints new cell and gene therapy manufacturing expert
- iNKT cell therapy platform update
- ZolpiMist Update
- SUDA signs Licence and Distribution Agreement with STADA
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics